Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim M Strohmaier

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Annual Review of Medicine|October 31, 2007
Advances in antifungal therapyCarole A Sable, Kim M Strohmaier, Jeffrey A Chodakewitz
International Journal of Antimicrobial Agents|September 20, 2011
Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief reportAngela L Ngai, Michael R Bourque, Robert J Lupinacci, et al.
Journal of Critical Care|September 18, 2007
Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trialMark J DiNubile, Robert J Lupinacci, Kim M Strohmaier, et al.
Antimicrobial Agents and Chemotherapy|March 17, 2010
Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin databaseArnaldo L Colombo, Angela L Ngai, Michael Bourque, et al.
AIDS (London, England)|April 28, 2011
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesJürgen K Rockstroh, Hedy Teppler, Jing Zhao, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2012
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)Eduardo Gotuzzo, Martin Markowitz, Winai Ratanasuwan, et al.
Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2008
Pharmacokinetics and safety of caspofungin in older infants and toddlersMichael Neely, Hasan S Jafri, Nita Seibel, et al.
The Pediatric Infectious Disease Journal|September 26, 2009
Safety experience with caspofungin in pediatric patientsTheoklis Zaoutis, Thomas Lehrnbecher, Andreas H Groll, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Annual Review of Medicine|October 31, 2007
Advances in antifungal therapyCarole A Sable, Kim M Strohmaier, Jeffrey A Chodakewitz
International Journal of Antimicrobial Agents|September 20, 2011
Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief reportAngela L Ngai, Michael R Bourque, Robert J Lupinacci, et al.
Journal of Critical Care|September 18, 2007
Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trialMark J DiNubile, Robert J Lupinacci, Kim M Strohmaier, et al.
Antimicrobial Agents and Chemotherapy|March 17, 2010
Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin databaseArnaldo L Colombo, Angela L Ngai, Michael Bourque, et al.
AIDS (London, England)|April 28, 2011
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesJürgen K Rockstroh, Hedy Teppler, Jing Zhao, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2012
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)Eduardo Gotuzzo, Martin Markowitz, Winai Ratanasuwan, et al.
Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2008
Pharmacokinetics and safety of caspofungin in older infants and toddlersMichael Neely, Hasan S Jafri, Nita Seibel, et al.
The Pediatric Infectious Disease Journal|September 26, 2009
Safety experience with caspofungin in pediatric patientsTheoklis Zaoutis, Thomas Lehrnbecher, Andreas H Groll, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Pageof 2